OQROGet OQRO Pro
Insider trade

United Therapeutics (UTHR)PRESIDENT AND COO sold ~$7.01M

Michael Benkowitz, PRESIDENT AND COO at United Therapeutics, sold ~$7.01M of United Therapeutics shares.

~$7.01M
Approx. value · 15K sh @ $479.51
Traded
Jan 12, 2026
Filed
Jan 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  2. Oct 31, 2025CongressDisclosed sale of UTHR — reported range $1,001 - $15,000
  3. Nov 10, 2025Insider · 3 peopleInsiders: 14 sales (~$21.5M)
  4. Nov 11, 2025Insider · 1 personInsiders: 3 sales (~$1.8M)
  5. Nov 12, 2025Insider · 1 personInsiders: 6 sales (~$1.8M)
  6. Nov 13, 2025Insider · 2 peopleInsiders: 13 sales (~$6.4M)
  7. Nov 14, 2025Insider · 1 personInsiders: 4 sales (~$1.9M)
  8. Nov 17, 2025Insider · 3 peopleInsiders: 16 sales (~$22.3M)
  9. Nov 18, 2025Insider · 1 personInsiders: 3 sales (~$1.9M)
  10. Nov 19, 2025Insider · 1 personInsiders: 2 sales (~$1.9M)
  11. Nov 20, 2025Insider · 1 personInsiders: 3 sales (~$1.9M)
  12. Nov 21, 2025Insider · 1 personInsiders: 3 sales (~$1.9M)
  13. Nov 24, 2025Insider · 2 peopleInsiders: 7 sales (~$6.2M)
  14. Nov 25, 2025Insider · 1 personInsiders: 3 sales (~$1.9M)

What came next

  1. Jan 21, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On January 21, 2026, the Board of Directors (the “ Board ”) of United Therapeutics Corporation (the “ Company ”), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board.”
  2. Feb 25, 2026Company filing · Form 8-K · ResultsReported its results
  3. Mar 9, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  4. May 6, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for United Therapeutics

For United Therapeutics, OQRO holds 791 insider filings (SEC Form 4 or Form 144), 18 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its UTHR page.

Other recent filings by Michael Benkowitz, PRESIDENT AND COO

The full history of Michael Benkowitz, PRESIDENT AND COO is on the profile page.

How this filing works

Other disclosures at United Therapeutics

Everything OQRO holds on this company is on its UTHR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data